Kalaris Therapeutics Inc

NASDAQ:KLRS

Biotechnology

Healthcare
$2.30 +3.52%

+$0.16 today

Market cap
$54.75M
Beta
0.14
P/E (TTM)
-2.5
EPS (TTM)
-$1.86
52W Low $2.14High $11.88

Volume 0.07M

Average 0.08M

KLRS Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Kalaris Therapeutics IncNASDAQ: KLRS

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 65.9% from a year ago

Cash & equivalents stood at $34.43M at the end of Q1 FY2026, down 65.9% from a year earlier and down 64.9% from the prior quarter. Over 3 fiscal years it compounded at +217.7% a year.

Context

  • Cash & equivalents amounted to 31.4% of total assets at the end of Q1 FY2026, down 66.6 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -65.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$34.43M-64.9% QoQ
Last fiscal yearDec 2025
$98.05M-17.1% YoY
Year agoMar 2025
$100.97M-65.9% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-65.9%——
1 year-17.1%——
3-year CAGR+217.7%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
98.05M USD
Year-over-year change
-17.1%
4-year CAGR
-16.5%

Cash & Equivalents vs competitors

How KLRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -65.9% is the 8th highest of 9, against a peer median of -30.9%.
  • Cash & equivalents amounts to 31.4% of total assets for KLRS, versus a peer median of 48.7%.
KLRS Competitors
Cash & Equivalents for KLRS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OVIDOvid Therapeutics Inc.Mar 2026$94.06M USD+345.0%-33.6%41.7%
STTKShattuck Labs, Inc.Mar 2026$90.42M USD+48.5%+4.6%88.5%
IMAImageneBio IncMar 2026$76.05M USD+106.9%-16.4%55.6%
STROSutro Biopharma, Inc.Mar 2026$73.68M USD-30.6%+7.1%30.4%
CNTXContext Therapeutics Inc.Mar 2026$54.53M USD-39.0%+23.0%92.6%
CNTBConnect Biopharma Holdings LimitedDec 2025$38.35M USD-51.0%-21.4%68.4%
KLRSKalaris Therapeutics IncMar 2026$34.43M USD-65.9%+217.7%31.4%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$20.96M USD-31.1%-36.1%19.8%
IFRXInflaRx N.V.Mar 2026€15.01M EUR-68.3%-0.5%30.7%
Peer median (excluding KLRS) —-30.9%-8.5%48.7%

Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents201.66M3.06M3.17M118.29M98.05M
Short-term Investments46.46M00019.93M
Net Receivables50K0000
Inventory00000
Other Current Assets5.18M3K17K257K78K
Total Current Assets253.35M3.9M3.33M118.55M118.81M
Property, Plant & Equipment (Net)31.29M0001.48M
Goodwill00000
Intangible Assets00000
Long-term Investments852K000499K
Tax Assets00000
Other Non-current Assets1.1M000953K
Total Non-current Assets33.25M0002.93M
Total Assets286.59M3.9M3.33M118.55M121.74M
Account Payables8.36M2.76M2.36M247K1.28M
Short-term Debt6.59M000316K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities15.03M296K540K1.96M6.52M
Total Current Liabilities37.85M5.69M3.94M5.24M9.71M
Long-term Debt03.25M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities025.23M44.41M032.08M
Total Non-current Liabilities23.48M28.48M44.41M033.21M
Total Liabilities61.33M34.17M48.35M5.24M42.92M
Common Stock7K0002K
Retained Earnings(297.07M)(32.7M)(47.39M)(714.96M)(160M)
Accumulated OCI(155K)00(135K)6K
Other Stockholders Equity00000
Minority Interest00000
Total Equity225.27M(30.27M)(45.02M)113.31M78.81M
Total Debt30.07M3.25M001.45M
Net Debt(171.6M)194K(3.17M)(118.29M)(96.61M)

Kalaris Therapeutics Inc

NASDAQ:KLRS

Intrinsic Alpha fair value

Locked

Current Price

$2.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.